

Betamethasone Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.0	06.04.2024	1274115-00018	Date of first issue: 12.02.2017

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1	Product identifier Trade name	:	Betamethasone Injection Formulation
1.2	Relevant identified uses of th	ne s	ubstance or mixture and uses advised against
	Use of the Sub- stance/Mixture	:	Pharmaceutical
	Recommended restrictions on use	:	Not applicable
1.3	Details of the supplier of the	saf	ety data sheet
	Company	:	Organon & Co. 30 Hudson Street, 33nd floor 07302 Jersey City, New Jersey, U.S.A
	Telephone	:	+1-551-430-6000
	E-mail address of person responsible for the SDS	:	EHSSTEWARD@organon.com

1.4 Emergency telephone number

+1-215-631-6999

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 1B Specific target organ toxicity - repeated exposure, Category 1 Long-term (chronic) aquatic hazard, Category 1 H360D: May damage the unborn child. H372: Causes damage to organs through prolonged or repeated exposure. H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

1

Hazard pictograms

Hazard statements



Signal word

: H360D May damage the unborn child.



Betamethasone Injection Formulation

Version 6.0	Revision Date: 06.04.2024	SDS Number: 1274115-00018	Date of last issue: 30.09.2023 Date of first issue: 12.02.2017
		peated exposure	damage to organs through prolonged or re- c to aquatic life with long lasting effects.
Preca	utionary statements	P264 Wash sk P273 Avoid rel	pecial instructions before use. in thoroughly after handling. ease to the environment. otective gloves/ protective clothing/ eye protec- ion.
		Response: P308 + P313 I attention. P391 Collect s	F exposed or concerned: Get medical advice/ pillage.

Hazardous components which must be listed on the label: betamethasone

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Benzyl alcohol	100-51-6 202-859-9 603-057-00-5	Acute Tox. 4; H302 Acute Tox. 4; H332 Eye Irrit. 2; H319 Acute toxicity esti- mate Acute oral toxicity: 1.620 mg/kg	>= 0,1 - < 1

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.0	06.04.2024	1274115-00018	Date of first issue: 12.02.2017
betam	nethasone	378-44-9 206-825-4	Acute Tox. 2; H330 Repr. 1B; H360D STOT RE 1; H372 (Pituitary gland,

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.



Betamethasone Injection Formulation

Versi 6.0	ion	Revision Date: 06.04.2024		OS Number: 74115-00018	Date of last issue: 30.09.2023 Date of first issue: 12.02.2017	
If swallowed		:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.			
4.2 M	lost im	portant symptoms a	nd e	effects, both acut	e and delayed	
	Risks		:	May damage the unborn child. Causes damage to organs through prolonged or repeated exposure.		
4.3 In	ndicatio	on of any immediate	meo	dical attention and	d special treatment needed	
	Treatm	-	:		ically and supportively.	
SEC	TION	5: Firefighting mea	sur	es		
020			oui			
5.1 E	Extingu	ishing media				
S	Suitable	e extinguishing media	:	Water spray Alcohol-resistant Carbon dioxide (Dry chemical		
	Unsuita media	ble extinguishing	:	None known.		
5.2 S	special	hazards arising from	the	e substance or mi	xture	
S	-	c hazards during fire-			bustion products may be a hazard to health.	
	Hazard ucts	ous combustion prod-	:	Carbon oxides		
5.3 A	dvice	for firefighters				
S		protective equipment	:		e, wear self-contained breathing apparatus. tective equipment.	
	Specific ods	c extinguishing meth-	:	cumstances and	g measures that are appropriate to local cir- the surrounding environment.	

Remove undamaged containers from fire area if it is safe to do so.

Use water spray to cool unopened containers.

Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions	: Use personal protective equipment.
	Follow safe handling advice (see section 7) and personal pro-
	tective equipment recommendations (see section 8).

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone Injection Formulation

Version 6.0	Revision Date: 06.04.2024	SDS Number: 1274115-00018	Date of last issue: 30.09.2023 Date of first issue: 12.02.2017		
6.2 Enviror	nmental precautions				
Environmental precautions		Prevent further Prevent spread barriers). Retain and disp Local authoritie	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.		
6.3 Method	Is and material for co	ntainment and clea	ning up		
Methods for cleaning up		For large spills ment to keep n be pumped, sto Clean up rema bent. Local or nation posal of this ma employed in th mine which reg Sections 13 an	hert absorbent material. provide dyking or other appropriate contain- material from spreading. If dyked material can pre recovered material in appropriate container. ining materials from spill with suitable absor- al regulations may apply to releases and dis- aterial, as well as those materials and items e cleanup of releases. You will need to deter- julations are applicable. d 15 of this SDS provide information regarding national requirements.		

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures	: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation	: If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling	 Do not get on skin or clothing. Do not breathe mist or vapours. Do not swallow. Avoid contact with eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Keep container tightly closed. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the continuer to the conti
Hygiene measures	 environment. If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment,



Betamethasone Injection Formulation

Version 6.0	Revision Date: 06.04.2024	SDS Number: 1274115-00018	Date of last issue: 30.09.2023 Date of first issue: 12.02.2017	
		industrial hygie	gowning and decontamination procedures, ene monitoring, medical surveillance and the trative controls.	
7.2 Condit	ions for safe storage,	including any inco	ompatibilities	
Requirements for storage areas and containers			Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.	
Advice	e on common storage	Strong oxidizir	ubstances and mixtures	
-	c end use(s) ic use(s)	: No data availa	ble	

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form	Control parameters	Basis
		of exposure)		
betamethasone	378-44-9	TWA	1 µg/m3 (OEB 4)	Internal
	Further inform	ation: Skin		
		Wipe limit	10 μg/100 cm²	Internal

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

Substance name	End Use	Exposure routes	Potential health ef- fects	Value
Benzyl alcohol	Workers	Inhalation	Long-term systemic effects	22 mg/m3
	Workers	Inhalation	Acute systemic ef- fects	110 mg/m3
	Workers	Skin contact	Long-term systemic effects	8 mg/kg bw/day
	Workers	Skin contact	Acute systemic ef- fects	40 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	5,4 mg/m3
	Consumers	Inhalation	Acute systemic ef- fects	27 mg/m3
	Consumers	Skin contact	Long-term systemic effects	4 mg/kg bw/day
	Consumers	Skin contact	Acute systemic ef- fects	20 mg/kg bw/day

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023	
6.0	06.04.2024	1274115-00018	Date of first issue: 12.02.2017	

Consumers	Ingestion	Long-term systemic effects	4 mg/kg bw/day
Consumers	Ingestion	Acute systemic ef- fects	20 mg/kg bw/day

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

Substance name	Environmental Compartment	Value
Benzyl alcohol	Fresh water	1 mg/l
	Marine water	0,1 mg/l
	Intermittent use/release	2,3 mg/l
	Sewage treatment plant	39 mg/l
	Fresh water sediment	5,27 mg/kg
	Marine sediment	0,527 mg/kg
	Soil	0,456 mg/kg

8.2 Exposure controls

Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

Personal protective equipment

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection		
Material	:	Chemical-resistant gloves
Remarks Skin and body protection	:	Consider double gloving. Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection Filter type	:	If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Equipment should conform to NS EN 143 Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Versi 6.0	on	Revision Date: 06.04.2024		S Number: /4115-00018	Date of last issue: 30.09.2023 Date of first issue: 12.02.2017
	Physica	l state	:	liquid	
	Colour		:	No data available	
	Odour		:	No data available	•
	Odour 1	Threshold	:	No data available	
	Melting	point/freezing point	:	No data available	
	Initial bo range	biling point and boiling	:	No data available	
	Flamma	ability (solid, gas)	:	Not applicable	
	Flamma	ability (liquids)	:	No data available	
		explosion limit / Upper bility limit	:	No data available	
		explosion limit / Lower bility limit	:	No data available	
	Flash p	oint	:	No data available	
	Auto-igr	nition temperature	:	No data available	
	Decomp	position temperature	:	No data available	
	рН		:	No data available	
,	Viscosit Visc	y osity, kinematic	:	No data available	
:	Solubilit Wate	y(ies) er solubility	:	No data available	
	Partitior octanol/	n coefficient: n- /water	:	Not applicable	
,	Vapour	pressure	:	No data available	
	Relative	e density	:	No data available	
	Density		:	No data available	
	Relative	e vapour density	:	No data available	
		characteristics cle size	:	Not applicable	



Version 6.0	Revision Date: 06.04.2024		S Number: 74115-00018	Date of last issue: 30.09.2023 Date of first issue: 12.02.2017
	information osives	:	Not explosive	
Oxidi	zing properties	: The substance or mixture is not classified as oxidizing.		
Evap	oration rate	:	No data available	9
SECTION	N 10: Stability and rea	acti	vity	
10.1 Reac Not c	:tivity lassified as a reactivity h	aza	rd.	
	nical stability e under normal conditior	ns.		
10.3 Poss	sibility of hazardous rea	actio	ons	
Haza	rdous reactions	:	Can react with st	rong oxidizing agents.
10.4 Cond	ditions to avoid			
	litions to avoid	:	None known.	
10.5 Inco	mpatible materials			
	rials to avoid	:	Oxidizing agents	
10.6 Haza	Indous decomposition	oroc	lucts	
	azardous decomposition			
SECTION	N 11: Toxicological ir	nfor	mation	
	-			
				ulation (EC) No 1272/2008
Inforr expos	nation on likely routes of sure	•	Inhalation Skin contact	
олро			Ingestion	
			Eye contact	
	e toxicity			
	lassified based on availa	ble	intormation.	
Prod		-		
Acute	e inhalation toxicity	:	Acute toxicity esti Exposure time: 4 Test atmosphere: Method: Calculati	h dust/mist
Com	ponents:			
Benz	yl alcohol:			
	•			



Version 6.0	Revision Date: 06.04.2024		S Number: 4115-00018	Date of last issue: 30.09.2023 Date of first issue: 12.02.2017		
Acute	oral toxicity	:	LD50 (Rat): 1.620	mg/kg		
Acute	inhalation toxicity	-	 LC50 (Rat): > 4,178 mg/l Exposure time: 4 h Test atmosphere: dust/mist Method: OECD Test Guideline 403 			
betan	nethasone:					
Acute	oral toxicity	:	LD50 (Rat): > 5.00	00 mg/kg		
			LD50 (Mouse): > 4			
Acute	inhalation toxicity		LC50 (Rat): 0,4 m Exposure time: 4 l			
-	corrosion/irritation lassified based on avail	able ir	nformation.			
Com	oonents:					
Benz	yl alcohol:					
Speci Metho Resu	es od	: (Rabbit OECD Test Guide No skin irritation	line 404		
betan	nethasone:					
Speci Resul			Rabbit Mild skin irritation			
	us eye damage/eye iri					
Not c	lassified based on avail	able ir	nformation.			
<u>Com</u>	ponents:					
Benz	yl alcohol:					
Speci			Rabbit			
Metho Resu			OECD Test Guide Irritation to eyes, r	line 405 eversing within 21 days		
betar	nethasone:					
Speci	es	:	Rabbit			
Resu	lt	:	No eye irritation			
Resp	iratory or skin sensiti	sation	1			
-	sensitisation lassified based on avail	able ir	nformation.			
_	iratory sensitisation lassified based on avail	able ir	nformation.			

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone Injection Formulation

Version 6.0	Revision Date: 06.04.2024	-	OS Number: 74115-00018	Date of last issue: 30.09.2023 Date of first issue: 12.02.2017	
Comp	onents:				
Benzy	l alcohol:				
Test T Exposi Specie Method Result	ure routes s		 Maximisation Test Skin contact Guinea pig OECD Test Guideline 406 negative 		
betam	ethasone:				
	ure routes s	:	Dermal Guinea pig Weak sensitizer		
	cell mutagenicity issified based on availa	able	information.		
Comp	onents:				
	l alcohol:				
Genoto	oxicity in vitro	:	Test Type: Bacter Result: negative	ial reverse mutation assay (AMES)	
Genoto	oxicity in vivo	:	cytogenetic assay Species: Mouse	nalian erythrocyte micronucleus test (in vivo ′) : Intraperitoneal injection	
betam	ethasone:				
Genote	oxicity in vitro	:	Test Type: Bacter Result: negative	ial reverse mutation assay (AMES)	
			Test Type: In vitro Result: negative	o mammalian cell gene mutation test	
			Test Type: Chron Result: positive	nosome aberration test in vitro	
Genoto	oxicity in vivo	:	Test Type: Mamn cytogenetic assay Species: Mouse Application Route Result: equivocal		
Germ o sessm	cell mutagenicity- As- ent	:	Weight of evidend cell mutagen.	e does not support classification as a germ	

Carcinogenicity

Not classified based on available information.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone Injection Formulation

Version 6.0	Revision Date: 06.04.2024		9S Number: 74115-00018	Date of last issue: 30.09.2023 Date of first issue: 12.02.2017
Benzy Specie Applic Expos Metho	Components:Benzyl alcohol:SpeciesApplication RouteExposure timeMethodResult		Mouse Ingestion 103 weeks OECD Test Guide negative	eline 451
May d	ductive toxicity amage the unborn child	ł.		
	onents:			
	/I alcohol: s on fertility	:	Species: Rat Application Route Result: negative	y/early embryonic development : Ingestion on data from similar materials
Effects	s on foetal develop-	:	Test Type: Embry Species: Mouse Application Route Result: negative	ro-foetal development : Ingestion
betam	ethasone:			
Effects	s on foetal develop-	:	Application Route Developmental To	: Intramuscular oxicity: LOAEL: 0,05 mg/kg body weight ty, Malformations were observed.
				: Subcutaneous oxicity: LOAEL: 0,42 mg/kg body weight ions were observed.
				: Intramuscular oxicity: LOAEL: 1 mg/kg body weight ions were observed.
Repro sessm	ductive toxicity - As- ent	:	Clear evidence of animal experimer	adverse effects on development, based on ts.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Causes damage to organs through prolonged or repeated exposure.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone Injection Formulation

Version 6.0	Revision Date: 06.04.2024	SDS Number: 1274115-00018	Date of last issue: 30.09.2023 Date of first issue: 12.02.2017
betan Targe	oonents: nethasone: t Organs ssment	Adrenal gland	Immune system, muscle, thymus gland, Blood, e to organs through prolonged or repeated
Repe	ated dose toxicity		
Comp	oonents:		
Benzy	yl alcohol:		
	EL cation Route sure time	: Rat : 1,072 mg/l : inhalation (dust : 28 Days : OECD Test Gu	
betan	nethasone:		
Expos		: Rabbit : 0.05 % : Skin contact : 10 - 30 d : Pituitary gland,	Immune system, muscle
Expos		: Rat : 0.05 % : Skin contact : 8 Weeks : thymus gland	
Expos	es L ation Route sure time t Organs	: Mouse : 0.1 % : Skin contact : 8 Weeks : thymus gland	
Speci LOAE Applic Expos Targe		: Dog : 0,05 mg/kg : Oral : 28 d : Blood, thymus g	gland, Adrenal gland
-	ation toxicity assified based on ava	lable information.	

11.2 Information on other hazards

Endocrine disrupting properties

Product:



Betamethasone Injection Formulation

Version 6.0	Revision Date: 06.04.2024	SDS Number: 1274115-00018	Date of last issue: 30.09.2023 Date of first issue: 12.02.2017				
Assessment		ered to have REACH Artic (EU) 2017/2	: The substance/mixture does not contain components consid- ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.				
Expe	rience with human ex	kposure					
Comp	oonents:						
betan	nethasone:						
Inhala Skin o	ation contact	5 5	ns: Adrenal gland Redness, pruritis, Irritation				

SECTION 12: Ecological information

12.1 Toxicity

Components:

Benzyl alcohol:		
Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): 460 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 230 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): 770 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
		NOEC (Pseudokirchneriella subcapitata (green algae)): 310 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to daphnia and other aquatic invertebrates (Chron- ic toxicity)	:	NOEC: 51 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211
betamethasone:		
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Americamysis): > 50 mg/l Exposure time: 96 h
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 34 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Version 6.0	Revision Date: 06.04.2024		OS Number: 74115-00018	Date of last issue: 30.09.2023 Date of first issue: 12.02.2017
			mg/l Exposure time: 72 Method: OECD T	
Toxic icity)	city to fish (Chronic tox-	:	NOEC: 0,052 mg, Exposure time: 32 Species: Pimepha Method: OECD T	2 d ales promelas (fathead minnow)
			NOEC: 0,07 µg/l Exposure time: 2 Species: Oryzias Method: OECD T	latipes (Japanese medaka)
aqua	city to daphnia and other tic invertebrates (Chron- kicity)	:	NOEC: 8 mg/l Exposure time: 2' Species: Daphnia Method: OECD T	n magna (Water flea)
M-Fa toxic	actor (Chronic aquatic ity)	:	1.000	
12.2 Persistence and degradability				
Com	ponents:			
	zyl alcohol: egradability	:	Result: Readily bi Biodegradation: 9 Exposure time: 14	92 - 96 %
12.3 Bioa	occumulative potential			
Com	ponents:			
Parti	zyl alcohol: tion coefficient: n- nol/water	:	log Pow: 1,05	
Parti	methasone: tion coefficient: n- nol/water	:	log Pow: 2,11	
	ility in soil ata available			
12.5 Res	ults of PBT and vPvB as	se	ssment	
Prod	luct:			
Asse	essment	:		ixture contains no components considered stent, bioaccumulative and toxic (PBT), or

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.0	06.04.2024	1274115-00018	Date of first issue: 12.02.2017

very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

Product:

Assessment

: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 13: Disposal considerations

13.1 Waste treatment methods	
Product	 Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	 Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN	:	UN 3082
ADR	:	UN 3082
RID	:	UN 3082
IMDO	; ;	UN 3082
ΙΑΤΑ	. :	UN 3082
14.2 UN p	proper shipping name	
ADN	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (betamethasone)
ADR	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (betamethasone)
RID	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (betamethasone)
IMDO	;	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Versior 6.0	n Revision Date: 06.04.2024	SDS Number: 1274115-00018	Date of last issue: 30.09.2023 Date of first issue: 12.02.2017
IA	ТА	N.O.S. (betamethason : Environmentall (betamethason	y hazardous substance, liquid, n.o.s.
14 3 Tr	ansport hazard class(es)	(betamethason	6)
14.5 11		Class	Subsidiary risks
Δ٦	DN	: 9	Subsidiary lisks
	DR	: 9	
RI		: 9	
	DG	: 9	
	TA	: 9	
	acking group		
Pa Cli Ha La Pa Cli Ha La Tu RI Pa	DN acking group assification Code azard Identification Number bels DR acking group assification Code azard Identification Number bels innel restriction code D acking group assification Code	: III : M6 : 90 : 9 : 9 : III : M6 : 90 : 9 : (-) : III : M6	
	azard Identification Number	: 90	
IM Pa La	bels DG acking group bels nS Code	: 9 : III : 9 : F-A, S-F	
IA Pa	TA (Cargo) acking instruction (cargo craft)	: 964	
Pa Pa	acking instruction (LQ) acking group bels	: Y964 : III : Miscellaneous	
Pa ge Pa Pa	TA (Passenger) acking instruction (passen- er aircraft) acking instruction (LQ) acking group bels	: 964 : Y964 : III : Miscellaneous	



Betamethasone Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.0	06.04.2024	1274115-00018	Date of first issue: 12.02.2017

14.5 Environmental hazards

Environmentally hazardous	:	yes
ADR Environmentally hazardous	:	yes
RID Environmentally hazardous	:	yes
IMDG Marine pollutant	:	yes
IATA (Passenger) Environmentally hazardous	:	yes
IATA (Cargo) Environmentally hazardous	:	yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments

Remarks

: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)	: Conditions of restriction for the fol- lowing entries should be considered: Number on list 75, 3
	Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the condi- tions in corresponding Regulation to determine whether an entry is appli- cable to the placing on the market or not.
	If you intend to use this product as tattoo ink, please contact your ven- dor.
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).	: Not applicable
REACH - List of substances subject to authorisation (Annex XIV)	: Not applicable



Betamethasone Injection Formulation

Version 6.0	Revision Date: 06.04.2024	SDS Number: 1274115-00018		ast issue: 30.09.2 rst issue: 12.02.2		
•	lation (EC) No 1005/2 the ozone layer	009 on substances that	at de- : N	Not applicable		
Regu	lation (EU) 2019/1021	on persistent organic	pollu- : N	Not applicable		
Regul ment	tants (recast) Regulation (EU) No 649/2012 of the European Parlia- : Not applicable ment and the Council concerning the export and import of dangerous chemicals					
Seves	Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.					
, E1		ENVIRONMEN		Quantity 1 100 t	Quantity 2 200 t	

Other regulations:

Note the Working Environment Act § 4-1 and § 4-2 on requirements for the employer to protect pregnant employees against discomfort and injury as a result of the work situation and the working environment.

Note the regulation on organization, leadership and participation, chapter 12 on the work of children and young people.

The components of this product are reported in the following inventories:

HAZARDS

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information	:	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.		
Full text of H-Statements				
H302	:	Harmful if swallowed.		
H319	:	Causes serious eye irritation.		
H330	:	Fatal if inhaled.		
H332	:	Harmful if inhaled.		
H360D	:	May damage the unborn child.		
H372	:	Causes damage to organs through prolonged or repeated exposure.		
H410	:	Very toxic to aquatic life with long lasting effects.		
Full text of other abbreviations				
Acute Tox. Aquatic Chronic Eye Irrit. Repr.	:	Acute toxicity Long-term (chronic) aquatic hazard Eye irritation Reproductive toxicity		



Betamethasone Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.0	06.04.2024	1274115-00018	Date of first issue: 12.02.2017

STOT RE

: Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIOC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Aquatic Chronic 1

Sources of key data used to compile the Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen- cy, http://echa.europa.eu/	
Classification of the mixture:			Classification procedure:
Repr. 1B	H3	50D	Calculation method
STOT RE 1	H3	72	Calculation method

H410

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be



Betamethasone Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.0	06.04.2024	1274115-00018	Date of first issue: 12.02.2017

considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN